Trending Now
Search for your favorite author
Newsletter This week's featured author
One article every two weeks from experts
Steve
Amy
Natalie
Tommaso
this month featured authors
or click on the right to get a complete list of authors
Continue to the categorySubscribe! Newsletter This week's featured author
One article every two weeks from pharma experts
Editor´s Pick
Subscribe to Editor´s Pick
Our selection of the most relevant daily news
AstraZeneca Imfinzi combination fails advanced lung cancer study
A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday.
Exclusive: Philips, under investigation in U.S. and Brazil, fired whistleblower who warned of graft
Healthcare giant Philips was warned of suspicious sales of its medical equipment to the Brazilian government, and failed to halt them, nearly a decade before an alleged bribery racket was exposed in the company's Brazil operations last year, Reuters has learned.
Drugmakers Endo, Allergan agree to $15 million in settlements in major opioid case
Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.
Teva launches generic version of EpiPen for young children
Teva Pharmaceutical Industries Ltd on Tuesday made its generic version of Mylan's EpiPen for young children available in most retail pharmacies at $300 for a 2-pack.
Sarepta shares sink 14% after shock FDA rejection
Shares of Sarepta Therapeutics Inc plunged 14% on Tuesday after the U.S. health regulator, in an unexpected move, declined to approve the drugmaker's newest treatment for a muscle-wasting disorder that mainly affects young boys.
Expert panel updates advice on BRCA cancer gene screening
(Reuters Health) - Mutations in the BRCA1 and BRCA2 genes are associated with increased risks for breast, ovarian, and other cancers, but only certain women stand to benefit from genetic testing, according to updated recommendations from the U.S. Preventive Services Task Force (USPSTF).
Drugmaker Endo to pay $10 million to settle opioid case ahead of trial
Endo International Plc on Tuesday said it had agreed to pay $10 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.
Teva to launch generic version of EpiPen for young children
Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack.
AstraZeneca diabetes drug shows promise in heart failure
AstraZeneca made strides on Tuesday toward its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly.
FDA declines to approve Sarepta’s second Duchenne treatment
Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the risk of infection and kidney toxicity.
Who is next in big pharma’s merger spree?
Consolidation in the U.S. healthcare industry, which has already witnessed a string of multi-billion dollar deals, is expected to remain a major theme for the rest of 2019.
Roche taps Lilly executive Garraway as chief medical officer
Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.
UK’s Johnson slams ‘mumbo-jumbo’ about vaccines after measles rates rise
Britons should get vaccinated against measles and ignore online "mumbo-jumbo" about dangers of the jabs, Prime Minister Boris Johnson said on Monday after a resurgence of the disease.
Look Who’s On the Move!
Subscribe to Look Who’s On the Move!
Roche taps Lilly executive Garraway as chief medical officer
Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.
Research and Development
Regulatory Affairs
Industry News